Ultralife (ULBI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Jun, 2026Executive summary
The annual meeting is scheduled for July 22, 2026, in Atlanta, GA, with voting available online, by phone, or by mail.
Proxy materials are distributed primarily via the internet to reduce environmental impact and costs.
Forward-looking statements regarding environmental and social goals are included, subject to risks and uncertainties.
Voting matters and shareholder proposals
Shareholders will vote to elect five directors for a one-year term.
Proposals include ratification of the independent auditor, a non-binding say-on-pay vote, and a vote on the frequency of future say-on-pay votes.
Shareholder proposals for the 2027 meeting must be received by January 28, 2027, for inclusion.
Board of directors and corporate governance
The board consists of five nominees, with a mix of industry, financial, and executive experience.
All directors except the CEO are independent per NASDAQ standards; the board chair is separate from the CEO.
Three standing committees: Audit and Finance, Corporate Development and Governance, and Compensation and Management.
Directors are expected to retire at 70 unless they own more than 5% of shares, in which case the limit is 75.
Stockholder recommendations for director nominations are considered using established criteria for diversity and expertise.
Latest events from Ultralife
- Annual meeting to vote on directors, auditor ratification, and executive pay proposals.ULBI
Proxy filing2 Jun 2026 - Revenue and margins declined, but a record $115.1 million backlog and new products support future growth.ULBI
Q1 20268 May 2026 - Q4 revenue up 10.6% year-over-year; impairment led to net loss, but backlog and new products support 2026 growth.ULBI
Q4 202510 Mar 2026 - Q2 revenue up 13% to $48.6M, but margins and net income declined; outlook for H2 is positive.ULBI
Q2 20253 Feb 2026 - Record segment sales, margin gains, and major debt reduction highlight Q2 2024.ULBI
Q2 20243 Feb 2026 - Q3 revenue and profit declined, but debt reduction and a $50M acquisition set up future growth.ULBI
Q3 202415 Jan 2026 - Q4 revenue was $43.9M, with Electrochem acquisition and strong backlog driving 2025 growth.ULBI
Q4 202424 Dec 2025 - Director elections, auditor ratification, and governance updates highlight the 2025 proxy.ULBI
Proxy Filing1 Dec 2025 - Vote on director elections and auditor ratification at the July 16, 2025 annual meeting.ULBI
Proxy Filing1 Dec 2025